Biocon’s Pertuzumab Biosimilar Receives EMA CHMP Positive Opinion, Moves Closer to European Market Entry

1. EMA CHMP Recommends Marketing Authorisation for Pebrilzo®

Biocon Biologics Ireland Limited, an indirect wholly-owned subsidiary of Biocon Biologics, submitted the marketing authorisation application for Pebrilzo®.

Following its review, the EMA’s CHMP issued a positive opinion recommending that marketing authorisation be granted for the pertuzumab biosimilar.

According to Biocon, Pebrilzo® is the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA’s tailored clinical development approach.

The recommendation represents progress in the regulatory pathway for the product. However, Pebrilzo® is not yet authorised for use in the European Union, pending the European Commission’s decision.

2. What Is Pebrilzo® and How Is It Used?

Pebrilzo® is a biosimilar containing pertuzumab, a monoclonal antibody that binds to the HER2 receptor. It is designed to inhibit the proliferation of tumour cells that overexpress HER2.

The product is recommended for use in combination with other cancer therapies in specified groups of adult patients with HER2-positive breast cancer.

The recommended indications include certain patients with early-stage, locally advanced, inflammatory, metastatic, or locally recurrent unresectable HER2-positive breast cancer, subject to the specific treatment criteria.

3. Tailored Clinical Development Approach: A Regulatory Milestone

Biocon stated that Pebrilzo® received its positive CHMP opinion under the EMA’s tailored clinical development approach.

The company’s application was supported by extensive structural and functional analytical characterisation, along with comparative clinical pharmacokinetic data.

According to Biocon, these assessments demonstrated high similarity between Pebrilzo® and the reference biologic, with no clinically meaningful differences in quality, safety or efficacy.

The development is notable because it highlights the role of advanced analytical and clinical pharmacology evidence in biosimilar development. It may also be relevant to how future biosimilar applications are evaluated under tailored regulatory pathways.

4. What Happens Next? European Commission Decision

The application will now proceed to the European Commission for its final review and decision on marketing authorisation.

If authorisation is granted, the product’s Summary of Product Characteristics (SmPC) will be made available in official European Union languages. The EMA is also expected to publish the European Public Assessment Report (EPAR) following the decision.

Until the European Commission grants marketing authorisation, Pebrilzo® cannot be marketed for authorised use in the European Union.

5. Management Commentary: Biocon Highlights Access to Cancer Therapies

Shreehas Tambe, CEO & Managing Director of Biocon, described the positive CHMP opinion as an important step towards expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe.

He also highlighted the regulatory significance of receiving a positive opinion under the EMA’s tailored clinical development approach, noting the role of advanced analytical and clinical pharmacology evidence in establishing biosimilarity.

The company’s announcement focuses on expanding access to biologic medicines and advancing its biosimilar portfolio through regulatory approvals in international markets.

6. What Does This Development Mean for Biocon Investors?

The positive CHMP opinion is a regulatory and product-development milestone for Biocon. However, the financial impact will depend on final approval, commercial launch, market access, and the product’s eventual contribution to revenue and profitability.

Investors tracking Biocon may monitor the following developments:

• European Commission approval: Whether Pebrilzo® receives final marketing authorisation.

• Commercial launch timeline: When the product may become commercially available in Europe.

• Market opportunity: The potential demand for pertuzumab biosimilars in the European oncology market.

• Revenue contribution: Whether the product contributes meaningfully to Biocon Biologics’ future revenue and earnings.

• Biosimilar pipeline: Further regulatory milestones and launches across Biocon’s broader biosimilar portfolio.

The press release does not disclose expected sales, pricing, launch timelines, or the projected financial contribution of Pebrilzo®. These remain important factors for assessing the commercial significance of the development.

About Biocon Limited

Biocon Limited is a Bengaluru-headquartered global biopharmaceutical company operating across biosimilars and generics. Its portfolio covers several therapeutic areas, including diabetes, oncology, obesity, cardiovascular diseases and immunology.

According to the company, it has commercialised 12 biosimilar products and more than 30 generic formulations globally. Its pipeline includes over 20 biosimilar assets, GLP-1 peptides and other complex generics.

Biocon operates in more than 120 countries and continues to focus on research, manufacturing and global commercialisation of medicines.

Conclusion

Biocon’s pertuzumab biosimilar, Pebrilzo®, has received a positive CHMP opinion recommending marketing authorisation in the European Union, marking an important regulatory milestone for its biosimilar business.

The next key development is the European Commission’s final decision. For investors, the focus will shift towards final approval, commercial launch, and the potential contribution of Pebrilzo® to Biocon’s oncology and biosimilar portfolio.